Available data indicate that TMB is in fact a more robust biomarker than others, including PD-L1 immunohistochemistry, the presence of TILs (tumor-infiltrating lymphocytes), or some clinico-pathologic variables [13,16]. This evidence concerns the gene CD274 and neoplasm.